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Erythrocyte microRNA sequencing
reveals differential expression in
relapsing-remitting multiple sclerosis
Kira Groen1,2, Vicki E. Maltby1,2, Rodney A. Lea2,3, Katherine A. Sanders4, J. Lynn Fink5, Rodney J. Scott2,6,7,
Lotti Tajouri8 and Jeannette Lechner-Scott1,2,9*
Abstract
Background: There is a paucity of knowledge concerning erythrocytes in the aetiology of Multiple Sclerosis (MS)
despite their potential to contribute to disease through impaired antioxidant capacity and altered haemorheological
features. Several studies have identified an abundance of erythrocyte miRNAs and variable profiles associated with
disease states, such as sickle cell disease and malaria. The aim of this study was to compare the erythrocyte miRNA
profile of relapsing-remitting MS (RRMS) patients to healthy sex- and age-matched controls.
Methods: Erythrocytes were purified by density-gradient centrifugation and RNA was extracted. Following library
preparation, samples were run on a HiSeq4000 Illumina instrument (paired-end 100 bp sequencing). Sequenced
erythrocyte miRNA profiles (9 patients and 9 controls) were analysed by DESeq2. Differentially expressed miRNAs
were validated by RT-qPCR using miR-152-3p as an endogenous control and replicated in a larger cohort (20
patients and 18 controls). After logarithmic transformation, differential expression was determined by two-tailed
unpaired t-tests. Logistic regression analysis was carried out and receiver operating characteristic (ROC) curves
were generated to determine biomarker potential.
Results: A total of 236 erythrocyte miRNAs were identified. Of twelve differentially expressed miRNAs in RRMS
two showed increased expression (adj. p < 0.05). Only modest fold-changes were evident across differentially
expressed miRNAs. RT-qPCR confirmed differential expression of miR-30b-5p (0.61 fold, p < 0.05) and miR-3200-3p
(0.36 fold, p < 0.01) in RRMS compared to healthy controls. Relative expression of miR-3200-5p (0.66 fold, NS p = 0.096)
also approached significance. MiR-3200-5p was positively correlated with cognition measured by audio-recorded
cognitive screen (r = 0.60; p < 0.01). MiR-3200-3p showed greatest biomarker potential as a single miRNA
(accuracy = 75.5%, p < 0.01, sensitivity = 72.7%, specificity = 84.0%). Combining miR-3200-3p, miR-3200-5p,
and miR-30b-5p into a composite biomarker increased accuracy to 83.0% (p < 0.05), sensitivity to 77.3%, and
specificity to 88.0%.
Conclusions: This is the first study to report differences in erythrocyte miRNAs in RRMS. While the role of
miRNAs in erythrocytes remains to be elucidated, differential expression of erythrocyte miRNAs may be exploited as
biomarkers and their potential contribution to MS pathology and cognition should be further investigated.
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Background
Multiple Sclerosis (MS) is an autoimmune disease of the
central nervous system (CNS) marked by lymphocytic
infiltration, demyelination, and neurodegeneration. It af-
fects approximately 2.5 million individuals worldwide.
MS is a heterogeneous disease, which is divided into
three disease courses with relapsing-remitting MS
(RRMS) being the most common (around 85% of the pa-
tient population) [1, 2]. Its aetiology is assumed to be
the interaction between environmental risk factors and
genetic predisposition [3], however the exact cause and
pathophysiology remain unclear.
MS is associated with activated peripheral and CNS-
resident immune cells [2] and it remains to be deter-
mined whether erythrocytes play a role in its pathology.
Erythrocytes are anucleate cells responsible primarily for
respiratory gas transport [4, 5], yet are also thought to
play a dynamic role in health and disease [6]. The poten-
tial involvement of erythrocytes in MS has been recently
reviewed [7]. Briefly, altered haemorheological features
of erythrocytes have been documented in MS and may
be contributing to blood-brain barrier (BBB) disruption,
a hallmark of MS pathology [2]. Furthermore, erythro-
cytes may contribute to increased levels of oxidative
stress in MS through impaired antioxidant enzyme cap-
acity [7]. In addition to MS pathology, disease-modifying
therapies (DMTs) also appear to affect erythrocytes. For
instance, natalizumab has been shown to result in previ-
ously undetected circulating erythrocyte precursors [8–
10]. Mitoxantrone [11], fingolimod [12], and dimethyl
fumarate [13] all have the potential to cause eryptosis,
erythrocyte-specific apoptosis, and interferon-β has been
shown to reduce red cell distribution width, possibly al-
tering haemorheological features [14].
More recent studies have focused on the potential use
of erythrocytes as MS biomarkers, using exogenous C-
peptide binding to erythrocytes [15]. Biomarkers that
can accurately reflect pathological and physiological pro-
cesses are crucial in diseases as complex and heteroge-
neous as MS. Such biomarkers are needed for diagnosis
and patient stratification, but also monitoring of treat-
ment efficacy and disease progression [16]. Current MS
diagnosis and monitoring relies on procedures such as
lumbar punctures and magnetic resonance imaging
(MRI) of the brain and spinal cord [2]. MicroRNA
(miRNA) profiles are gaining increasing interest as MS
biomarkers as they can reflect a range of ongoing patho-
logical and physiological processes simultaneously [16,
17]. MiRNAs are small (~ 22 bp) non-coding RNA mole-
cules that control gene expression at the post-
transcriptional level [18]. Studies have shown that in
peripheral blood mononuclear cell (PBMC) miRNAs can
accurately differentiate between MS patients and healthy
controls (HCs) [19, 20]; however, PBMCs only make up
a very small percentage of whole blood elements [4].
The majority of a blood sample, erythrocytes and
plasma, is discarded when assessing PBMCs. Addition-
ally, some DMTs, such as fingolimod, are known to de-
crease circulating PBMC numbers [21]. Consequently,
PBMC-derived miRNA profiles may not be the most
suitable biomarker to monitor MS. Erythrocytes, which
are abundant and can be quickly and cost-effectively
purified [4], may lend themselves as a superior option.
Recent expression studies have identified an amplitude
of miRNA transcripts in circulating erythrocytes [6, 22,
23]. Erythrocyte miRNA profiles were found to differ
from leukocyte and reticulocyte profiles, yet largely re-
flect the miRNA expression of whole blood [6]. While
the exact role of miRNAs in translationally inactive
erythrocytes [24] is still unknown, they may be involved
in intercellular communication through erythrocyte-
derived extracellular vesicles (EVs) [25], or remnants of
a functional erythrocyte precursor transcriptome [6, 24].
Despite uncertainty regarding the function of erythro-
cyte miRNAs, they have been found to differ in health
and disease [6]. The use of erythrocyte-specific miRNA
profiles is advantageous to whole blood miRNAs, as it
eliminates variation that may arise from differences in
whole blood cell composition. Erythrocytes have an aver-
age lifespan of 120 days in healthy individuals [4], but
reduced lifespans have been reported in athletes [26]
and some disease states [27]. Therefore, erythrocyte
miRNAs may prove to present a relatively stable picture
of miRNA expression, whereas translationally active cell
miRNA profiles tend to only provide a snapshot of
current miRNA expression, subjective to day-to-day
variation [28]. However, this hypothesis demands further
investigation.
Erythrocyte miRNAs may be exploited as biomarkers
for MS patient stratification, diagnosis, and monitoring
of treatment response and disease progression. Next-
generation sequencing (NGS) technology has the poten-
tial to identify novel MS miRNA signatures in erythro-
cytes. The aim of this study was to characterise the
erythrocyte miRNA profile of RRMS patients and com-
pare it to HCs using NGS technologies.
Methods
Sample collection
Ethical approval was obtained from the Bond University
Human Research Ethics Committee (RO-1382), the Uni-
versity of Newcastle Ethics Committee (H-505-0607),
and the Hunter New England Health Ethics Committee
(05/04/13/3.09). All participants gave written, informed
consent prior to enrolment. Whole blood was collected
into EDTA tubes from an initial cohort of 9 female
RRMS patients and 9 female healthy controls (HCs). A
further 20 female RRMS and 18 female HC samples
Groen et al. BMC Medical Genomics  (2018) 11:48 Page 2 of 12
were collected as part of the replication cohort. RRMS
diagnosis was defined according to the McDonald cri-
teria [29]. Participants who were pregnant, breastfeeding,
or suffering from an autoimmune condition other than
MS were excluded from the study. To minimise con-
founders associated with sex, only females were re-
cruited for this pilot study. Additional patient
information was obtained through MSBase, an obser-
vational database open to neurologists and health care
teams [30]. Participant characteristics are summarised
in Table 1.
Erythrocyte purification
Erythrocytes were purified from 10 ml whole blood by
density-gradient centrifugation. Lymphoprep (Stem Cell
Technologies, Canada) density-gradient media was used
according to manufacturer protocol. Plasma, PBMC
layer, density-gradient media, and top erythrocyte layer
were aspirated. The remaining erythrocyte pellet was
washed twice with Hanks-balanced salt solution (HBSS)
(GE Healthcare, United Kingdom).
Purity assessment of erythrocytes
Purity of obtained erythrocytes was assessed by flow cy-
tometry. One μl of erythrocyte pellet was stained with
FITC-conjugated CD235a (Clone 2B7; erythrocytes and
precursors) (BD Pharmingen, USA) and PE-conjugated
CD71 (M-A712; reticulocytes) (BD Pharmingen, USA).
All samples met a minimum purity cut-off of 95%.
Samples were analysed on FACS Canto II (BD Biosciences,
USA) using FACS Diva Software (BD Biosciences, USA).
RNA extraction
Total RNA was extracted from 300 μl erythrocyte pellets
with miRNeasy Kits (Qiagen, USA). Pellets were homog-
enized by vortexing samples for 1 min. Total RNA was
quantified using the broad-range RNA Kit for the Qubit
2.0 (Life Technologies, USA). RNA integrity was deter-
mined with the RNA 6000 Nano kit on a 2100 Bioanaly-
zer (Agilent Technologies, USA).
MiRNA sequencing and analysis
Library preparation and sequencing were performed by the
Diamantina Institute, University of Queensland, Brisbane,
Australia. Libraries were prepared with TruSeq Small RNA
Library Preparation kits (Illumina, USA). Samples were in-
dividually barcoded and then sequenced in two multiplexed
pools. Samples were run on the HiSeq4000 platform
(Illumina, USA) using paired-end sequencing (read length:
100 bp; coverage 1 million reads/sample). Sequencing reads
were de-multiplexed using CASAVA 1.8 software package
(Illumina, USA) and adapter sequences were trimmed using
Trim Galore! (https://www.bioinformatics.babraham.ac.uk/
projects/trim_galore/). Reads were aligned against miRBase
21 [31] using STAR [32] and NGS results were analysed by
DESeq2 [33]. Significance was adjusted for false discovery
rate (FDR) using the Benjamini-Hochberg procedure.
Table 1 Participant characteristics by cohort (sequencing and replication) and group (control subjects and RRMS patients)
Sequencing Cohort Replication Cohort
Control Subjects (n = 9) RRMS Patients (n = 9) Control Subjects (n = 18) RRMS Patients (n = 20)
Female 100% 100% 100% 100%
Caucasian 100% 90% 94% 100%
Age (years) 34.75 (±11.45) 42.44 (±9.66) 38.92 (± 9.89) 38.39 (±9.41)
Disease Duration (years) N/A 15.11 (±11.87) N/A 9.29 (±.5.52)
EDSS Score 2.00 (±1.32) 2.09 (±1.53)
Age at Onset (years) 27.94 (±8.48) 28.96 (± 8.79)
Number of Relapses 5.98 (±4.91) 6.35 (± 3.33)
Days since Last Relapse 1083.00 (±1271.81) 985 (±969.75)
Treatment Off Treatment 2 0
Dimethyl fumarate 2 0
Fingolimod 3 10
Natalizumab 2 10
Time on Treatment (years) 2.46 (±2.60) 3.57 (±2.20)
Number of Relapses on Treatment 0.56 (±0.73) 1.50 (±2.12)
Most recent ARCSa 78.33 (±26.76) 81.35 (±20.43)
Except for percentages and absolute numbers, all data is presented as mean (± SD). RRMS relapsing-remitting multiple sclerosis, EDSS extended disability status
scale, ARCS audio-recorded cognitive screen, SD standard deviation of the mean. aARCS are only reported for patients who completed an ARCS within a year of
sample collection (sequencing cohort n = 3; replication cohort n = 17)
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Reverse transcription quantitative polymerase chain
reaction (RT-qPCR) – Validation and replication
Differentially expressed erythrocyte miRNAs flagged by
NGS were confirmed in the initial NGS cohort and in a
replication cohort of 20 RRMS patients and 18 HCs
using TaqMan Advanced miRNA Assays (Assay IDs:
hsa-let-7f-5p: 478578, hsa-miR-30b-5p: 478007, hsa-
miR-32-5p: 478026, hsa-96-5p: 478215, hsa-181a-5p:
477857, hsa-miR-362-5p: 478059, hsa-598-3p: 478172,
hsa-652-3p: 478189, hsa-miR-660-5p: 478192, hsa-miR-
1294: 478693, hsa-miR-3200-3p: 478322, hsa-miR-3200-
5p: 478021; Applied Biosystems, Thermo Fisher Scien-
tific, USA). MiR-152-3p (hsa-miR-152-3p: 477921; Ap-
plied Biosystems, Thermo Fisher Scientific, USA) was
used as an endogenous normalisation control based on a
previous study investigating erythrocyte miRNAs by RT-
qPCR [6]. The expression of miR-152-3p did not differ
between RRMS patients and healthy controls in our se-
quencing cohort (Additional file 1: Table S1). Addition-
ally, miR-152-3p expression was not altered during
different stages of erythroid differentiation [34], it dem-
onstrated the least variation across 40 different human
tissue samples (Applied Biosystems, unpublished data,
see reference [6]), and showed great stability in a hepatic
study [34]. Relative expression was calculated using the
2-deltaCT method. All RT-qPCR experiments were per-
formed on a ViiA 7 (Applied Biosystems, USA) instru-
ment. IBM SPSS Statistics 24 was used for statistical
analysis. Since this was a relatively small discovery-based
project we chose to set a relaxed significance threshold
of 0.05 so as to reduce true positive rejection rate (Type
II error). Replication of significant hits using an inde-
pendent replication cohort was performed the reduce
the false positive rate (Type I error). Following logarith-
mic transformation, relative expression determined by
RT-qPCR was assessed by two-tailed unpaired Student’s
t-tests or ANOVA, depending on the number of groups
to be compared. Receiver operating characteristic (ROC)
curves were generated to assess the diagnostic value of
confirmed miRNAs and accuracy was determined by
area under the curve (AUC). Using relative expression
cut-off values that resulted in greatest sensitivity and
specificity for confirmed miRNAs, logistic regression
analysis was performed in IBM SPSS Statistics 24 to
determine the value of composite biomarkers using mul-
tiple confirmed miRNAs. Pearson correlation coeffi-
cients between confirmed miRNA and recorded disease
outcome measures (Table 1) were calculated.
MiRNA target prediction
MiRSystem was used to predict target genes of differen-
tially expressed miRNAs as it integrates seven prediction
algorithms and includes experimental validation of
miRNA-mRNA interactions [35].
Results
NGS was used to determine erythrocyte miRNA profiles
of 9 RRMS patients and 9 HCs. RT-qPCR was then uti-
lised to confirm differential expression of erythrocyte
miRNAs revealed by NGS in the sequencing cohort and
a more uniform replication cohort of 20 RRMS patients
and 18 HC samples. Participant characteristics of the se-
quencing and replication cohort are shown in Table 1.
Total RNA
Total erythrocyte RNA was extracted from 300 μl erythro-
cyte pellets (mean purity determined by flow cytometry
was 99%, with < 1% leukocytes and platelets; further detail
in Additional file 2: Table S2). Total erythrocyte RNA con-
tent in 10 ml whole blood was calculated by multiplying
RNA yields from one aliquot by the number of aliquots
obtained. Mean erythrocyte RNA yield obtained from
10 ml whole blood of MS patients (n = 29) was 20.12 μg
(± 17.02 μg), while the mean erythrocyte RNA content of
HCs (n = 27) was 12.44 μg (± 3.85 μg)/10 ml whole blood
(p < 0.05). RNA yield did not correlated with bench time
(time that passed between sample collection and process-
ing) (MS patients: r = 0.145, p = 0.553; HC: r = 0.169, p = 0.
502). Patients treated with natalizumab (32.35 μg/10 ml
whole blood) had significantly greater RNA yields than pa-
tients on fingolimod (15.52 μg/10 ml whole blood, p < 0.
01) and HCs (12.44 μg/10 ml whole blood, p < 0.001)
(Additional file 3: Figure S1).
Next-generation sequencing results
Following TruSeq Small RNA library preparation (Illumina,
USA), erythrocyte samples were sequenced by paired-end
100 bp sequencing on a HiSeq4000 (Illumina, USA) instru-
ment, aiming for 1 million reads per sample. NGS revealed
236 known miRNAs across patient and control erythro-
cytes. Normalised gene counts ranged from 1 to > 21,800
(Additional file 1: Table S1). Twelve erythrocyte miRNAs
were found to be differentially expressed in RRMS patients,
two of which, miR-1294 (1.55-fold, FDR adj. p < 0.05) and
let-7f-5p (1.73-fold, adj. p < 0.05), showed increased expres-
sion in RRMS compared to HCs. The remaining ten miR-
NAs, miR-181a-5p (0.45 fold, adj. p < 0.0001), miR-96-5p
(0.43 fold, adj. p < 0.05), miR-32-5p (0.49 fold, adj. p < 0.05),
miR-598-3p (0.53 fold, adj. p < 0.05), miR-362-5p (0.59 fold,
adj. p < 0.05), miR-30b-5p (0.60 fold, adj. p < 0.05), miR-
660-5p (0.64 fold, adj. p < 0.05), miR-652-3p (0.69 fold, adj.
p < 0.05), and miR-3200-3p and -5p (0.85 fold, adj. p < 0.01)
, showed decreased expression in RRMS compared to HCs
(Fig. 1). Four of the differentially expressed miRNAs (miR-
181a-5p, miR-362-5p, miR-598-3p, and miR-96-5p) were
very lowly expressed (< 100 reads) and only let-7f-5p, miR-
660-5p, and miR-652-3p reached more than 800 reads per
sample (Additional file 1: Table S1). No obvious clustering
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of patients and controls was evident when looking at global
differences in miRNA expression.
Reverse transcription quantitative polymerase chain
reaction results – Validation and replication
To validate NGS results, differentially expressed erythro-
cyte miRNAs were assessed by RT-qPCR in the original
sequencing cohort and a replication cohort.
Samples that did not meet our quality control cut-off
were removed from the dataset. Differential expression
trends in the discovery cohort (9 RRMS patients and 5
HCs) were replicated for all miRNAs with the exception
of let-7f-5p (Fig. 2). While the significance threshold
(p < 0.05) was not reached, this may be a result of in-
sufficient power to detect a significant change. With
the aim of assessing whether differential erythrocyte
miRNA expression was driven by DMTs as opposed
to disease, the original sequencing cohort was
segregated by DMT. No formal analysis was carried
out due to lack of power, yet visual representation
shows that with the exception of miR-3200-3p, miR-
3200-5p, and miR-652-3p, off treatment RRMS pa-
tients’ erythrocyte miRNA expression resembles that
of patients on DMT (Additional file 4: Figure S2).
Fig. 1 Violin plots of differentially expressed erythrocyte microRNAs identified by next-generation sequencing. The violin plots show normalised
gene counts of erythrocyte miRNAs that were found to be differentially expressed in RRMS patients (n = 9) compared to HCs (n = 9). Sequences
were aligned against miRBase 21 and differential expression was computed with DESeq2
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RT-qPCR experiments were replicated in a larger, more
uniform cohort of 20 RRMS patients and 18 HCs. De-
creased expression of miR-30b-5p (0.61 fold, p < 0.05) and
miR-3200-3p (0.36 fold, p < 0.01) was confirmed. Decreased
expression of miR-3200-5p (0.66 fold, NS p = 0.096)
approached significant threshold and was hence included
in further analysis (Fig. 3). To assess the biomarker poten-
tial of the confirmed miRNAs, ROC curve analysis was per-
formed for miRNAs that showed differential expression.
ROC curves graphically illustrate the diagnostic potential of
a binary outcome, in this case RRMS or HC, at different
thresholds. This allows the determination of true and false
positives for each of the thresholds, and specificity and sen-
sitivity to be calculated.
Cut-off values that maximised both specificity and sensi-
tivity were chosen. MiR-3200-3p showed the greatest bio-
marker potential being able to distinguish between RRMS
patients and HCs with 75.5% accuracy (p < 0.01; relative
expression cut-off: 0.81), 72.7% sensitivity, and 84.0% spe-
cificity. MiR-30b-5p and miR-3200-5p were able to differ-
entiate between RRMS and HCs with 70.5% (p < 0.05) and
65.8% (p = 0.064) accuracy, 68.2% and 59.1% sensitivity,
and 72.0% and 68.0% specificity respectively (Fig. 4;
Table 2). Combining relative expression (using cut-off
values in Table 2) of the three confirmed miRNAs (miR-
30b-5p, miR-3200-3p, and miR-3200-5p) in a binary logis-
tic regression with MS or HC being the dichotomous
Fig. 2 Log10(fold changes) of differentially expressed erythrocyte
microRNAs in relapsing-remitting Multiple Sclerosis. Log10(fold changes)
of differentially expressed erythrocyte miRNAs in relapsing-remitting
Multiple Sclerosis (RRMS) patients compared to healthy controls (HC) by
next-generation sequencing (9 RRMS patients and 9 HC) (blue) and
RT-qPCR (9 RRMS patients and 5 HC) (green)
Fig. 3 Tukey boxplot of differentially expressed erythrocyte microRNAs
confirmed by reverse transcription polymerase chain reaction. Tukey
boxplot of relative expression (2-deltaCT) (y-axis on a log scale) of
erythrocyte microRNAs in relapsing-remitting MS patients (n = 20;
green) and healthy controls (n = 18; blue). The blue dot represents an
outlier defined as deviating ≥1.5 fold from the upper/lower quartile.
* p < 0.05; ** p < 0.01; NS – not significant (p > 0.05)
Fig. 4 Receiver operating characteristic (ROC) curves for confirmed
erythrocyte microRNAs. ROC curves showing sensitivity and 1-specificity
at different thresholds for miR-3200-3p (green), miR-3200-5p (blue), and
miR-30b-5p (yellow)
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outcome, cases and controls could be assigned to their re-
spective category with overall accuracy of 83.0%, 77.3%
sensitivity, and 88.0% specificity (Table 3).
To determined clinical impact of differentially
expressed erythrocyte miRNAs Pearson correlation
coefficients between confirmed miRNAs and recorded
disease outcome measures (Table 1) were calculated.
Relative expression of miR-3200-5p was positively corre-
lated with patients most recent (within a year of sample
collection) cognitive assessment measured by audio-
recorded cognitive screen (ARCS) [36] (Pearson correl-
ation coefficient: 0.597; p < 0.01) (Fig. 5), as well as some
of the ARCS’ subdomains (Table 4). No further correla-
tions between confirmed miRNAs and disease outcome
measures, age, or bench time (elapsed time between
blood collection and processing) were identified.
There were no significant differences in miRNA levels
between patients on natalizumab (n = 12) and fingolimod
(n = 13) across the 12 assessed erythrocyte miRNAs.
MiRNA target prediction
Given that fold changes were only modest for all differ-
entially expressed miRNAs (Fig. 2), it is unlikely that a
single miRNA is significantly affecting target gene ex-
pression. To this end, it was reasoned that several miR-
NAs may work in concert to target a few specific
messenger RNAs (mRNAs). MiRSystem [35] was used to
identify genes targeted by several of the 12 differentially
expressed miRNAs identified by NGS. MiRSystem iden-
tified several genes targeted by four of the miRNAs
flagged by NGS and one gene, MIER 3 (mesoderm in-
duction early response 1, family member 3), was targeted
by five of the miRNAs identified as differentially
expressed by NGS (Table 5).
Discussion
This is the first study to compare the erythrocyte
miRNA profile of RRMS patients to HCs. Differentially
expressed erythrocyte miRNAs were identified in both
the sequencing and replication cohort. Three miRNAs
(miR-30b-5p, miR-3200-3p and miR-3200-5p) were
found to show decreased expression in RRMS erythro-
cytes compared to HC erythrocytes and the combination
of these miRNAs (miR-30b-5p, miR-3200-3p and miR-
3200-5p) into a composite biomarker, was able to differ-
entiate between RRMS patients and healthy controls
with 77.3% sensitivity, 88.0% specificity, overall accuracy
of 83.0%. Additionally, miR-3200-5p showed moderate
correlation with patients’ cognitive function, determined
by ARCS (correlation coefficient: 0.60; p < 0.01).
Current MS diagnosis is based on the 2013 revisions
to the McDonald criteria and clinical evidence is a cru-
cial component of this diagnosis [29]. Diagnosis and
monitoring of MS is underpinned by demyelinating le-
sions on MRI and supported by positive oligoclonal
bands in patients’ cerebrospinal fluid (CSF), requiring an
invasive lumbar puncture. There is no reliable blood test
that may guide diagnosis, monitoring, and selection of
treatment options [1, 2]. Differential expression of miR-
NAs in erythrocytes, which can be easily obtained as
Table 2 Receiver operating characteristic curve (ROC) results for the three confirmed erythrocyte microRNAs
MicroRNA RE Cut-Off Sensitivity (%) Specificity (%) Accuracy (%) p-value
miR-30b-5p 34.40 68.2 72.0 70.5 0.016
miR-3200-3p 0.81 72.7 84.0 75.5 0.003
miR-3200-5p 1.20 59.1 68.0 65.8 0.064
RE relative expression (2-deltaCT)
Table 3 Classification of relapsing-remitting Multiple Sclerosis




Observed RRMS 22 3 88.0
HC 5 17 77.3
Overall percentage 83.0
RRMS relapsing-remitting Multiple Sclerosis, HC healthy control
Fig. 5 Linear regression for RE of miR-3200-5p and patients’ ARCS
score. Relative expression (RE) of miR-3200-5p was positively correlated
(correlation coefficient 0.597; p < 0.01) with patients’ audio-recorded
cognitive screen (ARCS) score. Equations for the linear regression
model (black line) and 95% confidence intervals (blue lines) are shown
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part of other routine blood tests, indicates potential as
supportive biomarkers for MS diagnosis and monitoring,
reducing cost and patient discomfort associated with
current paraclinical investigations. Erythrocytes are
abundant in whole blood and thought to be translation-
ally inactive; therefore, they lend themselves as stable
biomarkers and should be further investigated. In order
to establish the true diagnostic potential of erythrocyte
miRNAs, their expression in MS needs to be compared
to other differential diagnoses, this should be addressed
by future studies. Differential diagnoses for MS include
vascular diseases, such as systemic vasculitis, conditions
of the brain and spinal cord, such as cerebellar ataxias,
and tumours and structural lesions in the CNS [3]. Thus
far, erythrocyte miRNAs have not been studied in dis-
eases that make up the differential diagnoses for MS.
Nonetheless, a study investigating whole blood miRNA
profiles in CIS/RRMS patients and patients with neuro-
myelitis optica spectrum disorders (NMOSD) found dif-
ferential expression of miR-30b in their discovery cohort
(20 CIS/RRMS patients and 20 NMOSD patients) and
replication cohort (19 RRMS/CIS patients and 18
NMOSD patients) [37]. As miR-30b was also found to
be differentially expressed in this study and whole blood
miRNAs have been found to reflect erythrocyte miRNAs
[6], the aforementioned finding [37] underpins the po-
tential erythrocyte miRNAs have as diagnostic bio-
markers for MS. Studies have also compared whole
blood miRNA profiles between stroke patients and
healthy controls, highlighting differential expression pat-
terns [38] and focusing on let-7e-5p expression [39].
With the differential expression patterns between stroke
patients and healthy controls [38, 39] differing from the
differential erythrocyte miRNA expression between
healthy controls and RRMS patients identified by this
study, one may argue that miRNAs can differentiate be-
tween stroke and RRMS patients, however this needs to
be confirmed through further investigation.
NGS of erythrocyte miRNAs of female RRMS patients
and HCs revealed 236 known miRNAs across RRMS
and HC samples. Several of the miRNAs flagged by
NGS, including the confirmed miR-3200-3p, have also
been identified in Alzheimer’s Disease (AD). Satoh et al.
identified decreased expression of let-7f-5p, miR-660-5p,
miR-1294, and miR-3200-3p, as well as several others
[40]. While not all trends match those in RRMS (Fig. 2),
involvement of the same miRNAs in two distinct neuro-
logical diseases suggests their overall importance for the
CNS. Satoh et al. used datasets from whole blood
samples [40], not isolated erythrocytes, which raises the
possibility of lymphocyte contamination. However, a pre-
vious study has shown that whole blood miRNAs largely
reflect erythrocyte miRNAs [6], allowing for comparison
between the two studies. Thus far, isolated erythrocyte
miRNAs have not been studied in diseases other than
malaria [41] and sickle cell disease [6].
One of the major symptoms of MS is cognitive impair-
ment, which may develop in the absence of clinical re-
lapse [2, 3]. Appropriate management of cognitive
impairment is only possible if it can be detected early in
the affected population [42]. Conventional neuropsycho-
logical assessment, the gold standard for detecting
changes in cognition, is time-consuming, requires a
Table 4 Pearson correlation coefficients between miR-3200-5p
and ARCS scores and subdomains
Pearson Correlation Coefficient p-value
Total ARCS 0.597 0.009
Quick ARCS 0.592 0.010
Memory Domain 0.427 0.077
Fluency Domain 0.499 0.035
Visuospatial Domain 0.314 0.205
Language Domain 0.282 0.256
Attention Domain 0.391 0.108
Speed of Writing 0.634 0.005
ARCS audio-recorded cognitive screen; significant correlations are highlighted
in bold
Table 5 MicroRNA target prediction results
Target Gene Gene Description Observed microRNA
MIER 3 mesoderm induction early response 1, family member 3 miR-181a-5p, miR-30b-5p, miR-32-5p, miR-362-5p, miR-660-5p
BCL2L11 BCL2-like 11 (apoptosis facilitator) miR-181a-5p, miR-30b-5p, miR-32-5p, miR-362-5p
SEC24A SEC24, family member A miR-181a-5p, miR-30b-5p, miR-32-5p, miR-660-5p
SCN3A sodium channel, voltage-gated type III, alpha subunit miR-30b-5p, miR-32-5p, miR-362-5p, miR-660-5p
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) miR-181a-5p, miR-30b-5p, miR-32-5p, miR-362-5p
YTHDF3 YTH domain family, member 3 miR-181a-5p, miR-30b-5p, miR-362-5p, miR-660-5p
NFAT5 nuclear factor of activated T-cells 5, tonicity response miR-181a-5p, miR-30b-5p, miR-32-5p, miR-660-5p
CPEB4 cytoplasmic polyadenylation element binding protein 4 miR-181a-5p, miR-30b-5p, miR-32-5p, miR-660-5p
LIN28 miR-181a-5p, miR-30b-5p, miR-32-5p, miR-598-3p
CNTN4 contactin 4 miR-181a-5p, miR-30b-5p, miR-32-5p, miR-362-5p
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trained psychologist, and is not feasible for routine clin-
ical practice. Consequently, other cognitive screening in-
struments, such as the ARCS, have been developed;
nonetheless, the ARCS still requires patients to spend
35 min in a quiet room [36]. No blood-borne biomarker
for cognitive impairment has been implemented in clin-
ical practice [43]. Differential expression of miR-3200-5p
was correlated with patients’ most recent ARCS score
(correlation coefficient: 0.597, p < 0.01), indicating that
this miRNA may serve as a biomarker for cognitive
function, reflecting global neuronal loss. The strongest
correlation was observed between the subdomain speed
of writing and the miRNA (correlation coefficient: 0.634,
p < 0.01). Speed of writing requires patients to write out
the word “table” as many times as possible in 30 s,
reflecting information processing and fine motor skills
[36]. The idea that circulating miRNAs may reflect cog-
nitive impairment is not new: two small studies looked
at mild cognitive impairment in the elderly and identi-
fied some miRNAs that correlated with mild cognitive
impairment with high sensitivity and specificity [42, 43].
Cognitive decline is an early sign of MS and may reflect
CNS damage more accurately than EDSS scores [44, 45].
Early detection for timely treatment and management
are key to improve outcomes in MS, yet current cogni-
tive screens are time and labour intensive and can be
distressing for patients. The correlation between miR-
3200-5p and patients’ARCS score indicates this miRNA’s
potential to be developed into a biomarker for cognitive
impairment. Longitudinal assessment and validation in a
larger cohort are necessary to confirm this hypothesis.
While a range of targets were predicted by miRSystem
[35], fold changes in differentially expressed miRNAs
were only minor, reducing the likelihood that a single
miRNA is affecting gene expression. Nonetheless, several
of the differentially expressed miRNAs were found to
target the same genes, potentially amplifying dysregula-
tion [18]. None of the predicted targets play an estab-
lished role in mature erythrocytes and MIER3 is not
known to play a role in MS. The role of miRNAs in
translationally inactive mature erythrocytes remains to
be elucidated [24]. It has been suggested that erythrocyte
miRNAs are remnants from earlier stages of erythrocyte
development, where they played crucial roles in cell
differentiation and maturation [6, 22]. Notwithstanding,
erythrocyte miRNAs may play a more active role,
functioning as intercellular communicators through
erythrocyte-derived EVs. EVs are small, membrane-
bound vesicles, containing proteins, nucleic acids, and
lipids, which can be derived from a variety of cells, in-
cluding erythrocytes [25].
None of the differentially expressed erythrocyte miR-
NAs were found to be highly abundant in erythrocytes
(some of the most abundant miRNAs were miR-25,
miR-144, miR-451, miR-182, and members of the let-7
family; Additional file 1: Table S1) and the reason for the
observed differential expression remains to be clarified.
Potential angles for investigation include stabilisation of
certain miRNAs through associations with protein com-
plexes, such as Argonaute proteins [22] and other non-
coding RNAs [18], as well as targeted packaging and loss
of certain miRNAs through EVs [25].
Recruited patients were on various DMTs (Table 1), some
of which are known to alter erythrocyte phenotypes [8–13].
To account for the treatment effects, patients were re-
cruited on a range of therapies, with the intent of identify-
ing miRNA signatures that were disease- rather than
treatment-specific. While lack of power did not allow for
formal comparisons between RRMS patients on DMTs and
untreated RRMS patients, visual comparison indicated that
expression of miR-3200-3p, miR-3200-5p, and miR-652-3p
might differ between these groups (Additional file 4: Figure
S2). These differences and the effect of DMTs on erythro-
cyte miRNA expression needs to be further investigated
and some of the findings of this study may be specific to
MS patients on DMTs. Differences between DMTs were
also assessed. Differential expression between natalizumab
and fingolimod treated patients was evident for let-7f-5p,
which showed increased expression in patients on fingoli-
mod compared to patients on natalizumab (data not
shown). While not statistically significant, this difference
may explain why the trend of differential expression could
not be replicated by RT-qPCR for let-7f-5p (Fig. 2). Neither
of the treatment groups showed differential let-7f-5p ex-
pression compared to healthy controls (data not shown).
Members of the let-7 family have been reported in other
erythrocyte miRNA studies [6, 22, 23], where they are
thought to be involved in erythropoiesis [46], and have also
been shown to be less expressed in MS patients [47]. Cox
et al. [47] used PAXGene (Qiagen, Germany) technology to
analyse whole blood miRNA expression. Lack of similarity
between identified miRNAs, other than let-7f, by Cox et al.
and in this study, may reflect differences in cell make up,
with PAXGene technology focussing mostly on leukocytes.
Nevertheless, the reason for the difference in miRNA ex-
pression between treatments remains unknown and war-
rants further investigation.
Total RNA obtained from 10 ml whole blood varied be-
tween 9.40 and 35.35 μg (Additional file 1: Figure S1). Both
reticulocytes and nucleated cells have been shown to
harbour greater amounts of total RNA than erythrocytes
[6]. Increased RNA yields from erythrocytes of patients
treated with natalizumab may reflect increased levels of cir-
culating erythrocyte precursors in these patients [8–10].
While low power to detect small differences in miRNA
species and the recruitment of patients on different
DMTs, some of which are known to alter erythrocytes
[8–13], should be addressed by future studies, these
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preliminary results indicate that erythrocyte miRNAs
should be incorporated into the growing list of MS bio-
markers. Future investigations should aim to recruit lar-
ger numbers of treatment-naïve patients (including male
MS patients), assess intra-individual variability, and
evaluate specificity of observed differential expression to
MS. In addition to healthy controls, future studies
should aim to recruit pathological controls suffering
from other systemic inflammatory, neurodegenerative,
and autoimmune diseases.
The potential importance of erythrocyte pellets to MS
and other diseases is starting to be recognized: Erythro-
cyte/granulocyte pellets are already being stored as part
of the UK ME/CFS Biobank [48] and future investiga-
tions into erythrocytes and MS, or other autoimmune
diseases, may provide a novel avenue for immunoregula-
tory prophylaxis and treatment options [49].
Conclusions
This is the first study to explore erythrocyte miRNAs in
RRMS. We find evidence to suggest that erythrocyte
miRNAs, particularly miR-30b-5p, miR-3200-3p and
miR-3200-5p, may be exploited as novel MS biomarkers
and miR-3200-5p may be developed into a biomarker
for cognitive decline. Further investigations are war-
ranted to substantiate these findings as erythrocytes can
be easily and cost-effectively purified and novel bio-
markers are required to aid diagnosis and stratification
of MS patients.
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Additional file 1: Table S1. Next-generation sequencing results of
erythrocyte microRNAs for 9 healthy controls and 9 relapsing-remitting
Multiple Sclerosis patients. (XLSX 27 kb)
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Additional file 4 Figure S2. Tukey boxplot of relative expression (2-deltaCt)
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